Journal of Advances in Medicine and Medical Research
33(19): 111-119, 2021; Article no.JAMMR.73568
ISSN: 2456-8899
(Past name: British Journal of Medicine and Medical Research, Past ISSN: 2231-0614,
NLM ID: 101570965)
Does Galectin3 Immunohistochemical Marker Help
in Diagnosing the Nature of Benign or Malignant
Thyroid Tumor?
Umm-e-Farwa1, Rehana Ramzan1, Mahwish Niaz2, Hassan Salim3,
Rabiya Fawad4, Nadia Tasawer5, Kashif Bangash6, Hassan Mumtaz7*
and Shahzaib Ahmad8
1
Department of Histopathology, Foundation University Medical College, Islamabad, Pakistan.
2
Shifa college of medicine, Shifa Tameer-e-Millat University, Islamabad, Pakistan.
3
Fauji Foundation Hospital, Rawalpindi, Pakistan.
4
Department of Pathology, Quetta Institute of medical sciences, Quetta Pakistan.
5
Department of Histopathology, Pakistan institute of medical sciences Islamabad, Pakistan.
6
Department of Urology, KRL Hospital Islamabad, Pakistan.
7
Clinical Research Center, Shifa International Hospital Islamabad, Pakistan.
8
King Edward Medical University, Pakistan.
Authors’ contributions
This work was carried out in collaboration among all authors. All authors read and approved the final
manuscript.
Article Information
DOI: 10.9734/JAMMR/2021/v33i1931085
Editor(s):
(1) Dr. Emmanouil (Manolis) Magiorkinis, General Hospital for Chest Diseases "Sotiria", Greece.
Reviewers:
(1) Shaimaa Mahmoud Mohamed Saleh, Assiut University, Egypt.
(2) Martha Lilia Tena-Suck, National Institute of Neurology and Neurosurgery, Mexico.
Complete Peer review History: https://www.sdiarticle4.com/review-history/73568
Original Research Article
Received 30 June 2021
Accepted 10 September 2021
Published 10 September 2021
ABSTRACT
Introduction: Galectin-3 has been reported quite accurate to detect or exclude malignancy in
nodules with prior indeterminate Fine Needle Aspiration Cytology and per operative findings.
Keeping this fact in mind, Galectin-3 can have a pivotal role in separating benign from the
malignant thyroid neoplasms.
We aim to determine the frequency and intensity of Galectin-3 immunohistochemical expression
among benign and malignant thyroid neoplasms confirmed on histopathology.
_____________________________________________________________________________________________________
*Corresponding author: E-mail: Hassanmumtaz.dr@gmail.com;
Farwa et al.; JAMMR, 33(19): 111-119, 2021; Article no.JAMMR.73568
Materials and Methods: We studied 78 thyroid specimens diagnosed with thyroid neoplasms on
histopathology. Out of these 39 were benign cases (follicular adenoma and hurthle cell adenoma)
and 39 were malignant cases (papillary thyroid carcinomas, follicular carcinoma, medullary
carcinoma and poorly differentiated carcinoma). Each specimen was examined grossly and
microscopically and checked for immunohistochemical staining pattern of Galectin-3 under the
microscope.
Results: Age range in this study was from 15 to 65 years with mean age of 44.97 ± 10.78 years.
Out of these 78 patients, 17 (21.79%) were male and 61 (78.21%) were female with male to female
ratio of 1:3.6. Frequency of positive Galectin-3 immuno histochemical expression among thyroid
neoplasms was found in 32 (41.03%) cases with Galectin-3 showing positive staining in 21
(53.85%) of all malignant and 11 (28.21%) of all benign cases .Among the malignant neoplasms,
positivity was seen most frequently in papillary thyroid carcinomas as compared to the other
malignancies.
Conclusion: This study concluded that positive Galectin-3 immunohistochemical expression is
more in malignant thyroid neoplasms (53.85%) as compare to the benign lesions (28.21%).
Therefore, we recommend that this marker cannot be used alone for the routine diagnosis of
malignant lesions as it has shown less sensitivity and specificity. Moreover it also has shown no
significant role in differentiating between the benign and the malignant thyroid neoplasms.
Keywords: Thyroid cancer; Immunohistochemical expression; Galectin-3; malignant; benign.
1. INTRODUCTION
Thyroid gland is an important part of the
endocrine system located at the base of the
neck. It is chiefly composed of two types of cells,
follicular and parafollicular cells. The follicular
cells make thyroxine, which has important
functional impacts on various systems and
general metabolism. The parafollicular cells, also
known as C cells arise from the neural crest and
are involved in the calcitonin production, which
has vital role in maintaining calcium homeostasis
[1].
Thyroid neoplasms including both benign and
malignant
lesions are
common entities
encountered in daily clinical practice. Most of the
lesions (95%) arise from the follicular epithelial
cells of the thyroid gland [2].
Thyroid cancer is the most common among the
endocrine tumors and its incidence has been
increasing in the last three decades [3]. An
estimated mortality rate of thyroid cancer is 0.5 to
10 cases per 100,000. The annual male and
female percentage is 6.3% and 7.1% for white
population, 4.3% and 8.4% for blacks and for
Asian population patients it is 3.4% and 6.4%
respectively [3]. These tumors can clinically
present as a solitary nodule along with the
normal thyroid gland or as a dominant nodule in
the background of a multinodular goiter. 5% of
the solitary thyroid nodules are found to be
neoplastic [4].
In Pakistan, thyroid neoplasms are common
especially in the northern areas, which are
mainly attributable to the iodine deficiency or
excess. Thyroid cancer accounts for 1.2% of all
the malignancies diagnosed in our country with
the papillary thyroid carcinoma being most
common. The female to male ratio in Pakistan is
reported as 2.2:1 [5].
Patients can present with both the features of
hyper and hypothyroidism in both benign and
malignant lesion. This makes it clinically difficult
to diagnose the exact underlying cause. Here
comes the role of histopathology, which can
correctly diagnose the lesion, but there are some
neoplasms
that
have
very
confusing
morphological details and these cannot be
exactly categorized into benign or malignant,
only on the basis of histopathology. This scenario
is mostly seen in the follicular and the Hurthle
cell neoplasms. The gross appearance and the
microscopic details are perplexing for a
pathologist. Moreover, the cytological details are
also much overlapping in various benign versus
malignant lesions [2].
The final diagnosis of the lesion being benign
and malignant has profound effects on the
clinical outcome and prognosis of the patient.
Several articles have reported the significance of
immune histochemical markers to solve this
problem. Galectin-3, p63 and Ki67 have been
reported quite accurate to detect or exclude
malignancy in nodules with prior indeterminate
112
Farwa et al.; JAMMR, 33(19): 111-119, 2021; Article no.JAMMR.73568
Fine Needle Aspiration
operative findings [6].
Cytology
and
per
In this study, role of Galectin-3 will be quantified
to differentiate and classify the thyroid lesions
into benign and malignant categories. Galectin-3
belongs to the family of lectins. Galectin-3 is
synthesized in both the nucleus and cytoplasm,
and also expressed at the cell surface. It is also
found extracellularly in the general circulation.
Galectin-3 specifically binds to the beta
galactoside containing intracellular, extracellular
and cell surface associated glycol conjugates so
it is over expressed in oncogenic pathology of
thyroid [7-8].
In Pakistan, limited data is available regarding
the role of galectin-3 as a diagnostic tool to
differentiate malignant thyroid neoplasms from
benign lesions. So, this study can have beneficial
effects in the diagnostics and further treatment of
such lesions.
2. MATERIALS AND METHODS
This descriptive, cross-sectional study was
conducted from 5th November 2017 to 4th May
2018 in the Department of Histopathology,
Foundation
University
Medical
College,
Islamabad Campus & Department of Surgery,
Fauji Foundation Hospital, Rawalpindi. There
was a total of 78 thyroid specimens included in
this study (39 benign and 39 malignant
neoplasms). All of these patients were operated
at the Department of Surgery, Fauji Foundation
Hospital Rawalpindi during a period of six
th
th
months from 5 November 2017 to 4 May 2018.
The specimens were processed in the
department of Histopathology, Foundation
University Medical College Islamabad. The
benign conditions included Follicular adenoma
and Hurthle cell adenoma. The malignant
conditions included Papillary thyroid carcinoma
(both classic type and follicular variant), Follicular
thyroid carcinoma, Medullary thyroid carcinoma
and poorly differentiated carcinoma.
The hospital ethical committee granted the
approval for data collection. The data included
patient’s
demographic
details,
clinical
presentation, previous laboratory test record and
clinical suspicion. The specimens were examined
both grossly and microscopically in the
laboratory. The thyroid specimens were fixed in
10% formalin and were sliced properly. The
representative sections were processed in the
tissue processor (SAKURA TISSUE TEK-R
TEC5 MODEL 220-240) for the paraffin
sectioning.After this step, 4-5µm thick sections
were cut using rotatory microtome (SAKURA
ACCU-CUT MODEL SRM 200 CW). Hematoxylin
and eosin stain (H&E) was used for staining the
slides and get them ready to see under the
microscope.
For the immunohistochemistry, representative
histological sections of the thyroid neoplasm
were used. The sections were deparaffinised by
xylene and then were rehydrated by ethanol. Trisodium citrate buffer (pH 6.0 to 6.2) was used for
the antigen retrieval. When the slides came back
to room temperature, endogenous peroxidase
activity was blocked by 0.6% H2O2. After this
step lyophilized mouse monoclonal Galectin-3
antibody in the dilution of 1:100 was applied for
an hour. Washing was done with tris- buffered
saline (TBS). Then for 20 minutes super
enhancer was added. Polymer horseradish
peroxidase (HRP) was applied for 30 minutes as
a secondary antibody and washing was done
again with TBS. Subsequently Diamine
Benzidine (DAB) chromogen was applied for 5
minutes. Mayer’s Haematoxylin was used for
counter staining followed by clearing and
mounting. Positive and negative controls were
also applied.
Two consultant histopathologists examined the
H&E stain and immunohistochemical marker
(Galectin-3) under the Olympus light microscope.
The sections with the best staining were selected
for
examination
and
reported
likewise.
Morphology and staining was noted and grading
of Galectin-3 was done by Weber KB et al and
Hermann ME et al guidelines. The intensity and
distribution of Galectin-3 staining (cytoplasmic)
on a scale of 0 to 3 was done as follows:
0 No staining
1+ Weak/slight staining
2+ Moderate staining
3+ Intense staining
The proportion of stained cells was interpreted
as;
1+ < 5% of cells
2+ 5% to 50% of cells
3+ >50% of cells
The lesions with the particular cytoplasmic
staining of more than 5% of the tumor cells was
taken as positive for Galectin-3 regardless of its
intensity.
113
Farwa et al.; JAMMR, 33(19): 111-119, 2021; Article no.JAMMR.73568
3. RESULTS
Age range in this study was from 15 to 65 years
with mean age of 44.97 ± 10.78 years as shown
in Table- 1. Out of these 78 patients, 61
(78.21%) were female and 17 (21.79%) were
male with female to male ratio of 3.6:1 (Fig. 1).
On the basis of histopathological diagnosis half
(39) cases belonged to benign neoplasms and
other half (39) were diagnosed as malignant
neoplasms as shown in Fig. 2.
Frequency of positive Galectin-3 immunohistochemical expression among thyroid neoplasms
was found in 32 out of 78 (41.03%) cases while
46 out of total 78 (58.97%) were showing
negative galectin-3 staining (Fig. 3).
A detailed look at the further breakdown of
galectin-3 staining among benign neoplasms
reveal that 11(28.1%) among 39 benign cases
were positive for the stain. For the malignant
neoplasms, total 21(53.85%) among 39 cases
were positive. On the other side 28(71.79%)
benign cases and 18(46.15%) malignant cases
showed negative galectin-3 staining. The p-value
calculated was 0.021 which is not significant
(Table 2).
The Stratification of Galectin-3 immunohistochemical expression with respect to age groups
showed total 27 cases within the age range of
15- 40 years out of which 10 cases were positive.
Total 51 cases belonged to the age range of 4165 years out of which 22 showed positive
galectin-3 staining. The p-value calculated was
0.602 which is again insignificant (Table 3).
Similarly Table 4 shows the breakdown of the
cases according to gender. Total 8 out of 17
cases among male patients were positive for
Galectin-3 and 24 out of 61 cases of female
patients were showing the positive staining. The
p-value calculated was 0.567 which is again
insignificant.
The breakdown of Galectin-3 positivity in the
various histological types of malignant and
benign thyroid neoplasms is also shown in Figs
4,5 respectively.
17 (21.79%)
61 (78.21%)
Male
Female
Fig. 1. Distribution of patients according to Gender (n=78)
Table 1. Age distribution of patients (n=78), having Mean ± SD = 44.97 ± 10.78 years
Age (in years)
15-40
41-65
Total
No. of Patients
27
51
78
%age
34.62
65.38
100.0
Table 2. Stratification of Galectin-3 immunohistochemical expression among benign and
malignant thyroid neoplasms
Benign
Malignant
Galectin-3 immunohistochemical expression
Positive
Negative
11 (28.21%)
28 (71.79%)
21 (53.85%)
18 (46.15%)
114
p-value
0.021
Farwa et al.; JAMMR, 33(19): 111-119, 2021; Article no.JAMMR.73568
60%
39 (50%)
39 (50%)
Benign
Malignant
50%
40%
30%
20%
10%
0%
Fig. 2. Distribution of patients according to histopathological features (n=78)
32 (41.03%)
46 (58.97%)
Positive
Negative
Fig. 3. Frequency of Galectin-3 immunohistochemical expression among thyroid neoplasms
confirmed on histopathology (n=78)
Table 3. Stratification of Galectin-3 immunohistochemical expression with respect to age
groups
15-40 years
41-65 years
Galectin-3 immunohistochemical expression
Positive
Negative
10
17
22
29
p-value
0.602
Table 4. Stratification of Galectin-3 immunohistochemical expression with respect to gender
Male
Female
Galectin-3 immunohistochemical expression
Positive
Negative
08
09
24
37
115
p-value
0.567
Farwa et al.; JAMMR, 33(19): 111-119, 2021; Article no.JAMMR.73568
30
25
20
15
10
5
0
26
15
11
6 8
4
2
Negative
4
0
Positive
1 0 1
Total Cases
Fig. 4. Galectin-3 staining in various histological types of Thyroid carcinomas
40
30
20
10
0
29
21
8
7
Follicular Adenoma
Negative
3
10
Hurthle Cell
Adenoma
Postive
Total Cases
Fig. 5. Galectin-3 staining in various histological types of Thyroid adenomas
4. DISCUSSION
Recent
studies
pointed
to
some
immunohistochemical markers questioning their
diagnostic and prognostic utility in different
thyroid tumors. Among these, they have
deduced Galectin-3 to be a promising
marker.Galectin-3 is a unique member of an
ancient lectin family [9]. Galectin-3 is also
expressed in a variety of normal tissue and
tumors [10]. Malignant transformation of thyroid
cells has been found to be accompanied with
intense nuclear [10] localization of galectin-3 in
tumors [11]. Galectin-3 expression recently
emerged as a potential diagnostic and
prognostic marker of some cancers [12].
Although galectin-3 is not a universal and
unambiguous marker of thyroid cancers, it could
be a helpful parameter in diagnosis of these
tumors as well as possible potential therapeutic
target [13-16].
In 2015 a study was conducted in India
regarding the staining pattern of Galectin-3 in
thyroid neoplasms. The results showed 86%
sensitivity and 85% specificity, with Galectin-3
showing positive staining in 87% of all malignant
and 15% of all benign cases [2] In 2016, another
study was conducted in Italy to check the
diagnostic
accuracy
of
the
various
immunohistochemical stains and they found
galectin-3 to be 84.2% sensitive and 94.5%
specific in detecting the thyroid neoplasms [7].
In contrast, our study shows less frequency of
positive
Galectin-3
immunohistochemical
expression among thyroid neoplasms i.e. total
32 (41.03%) cases with Galectin-3 showing
positive staining in 53.85% of all malignant and
28.21% of all benign cases. In 2002 a study was
conducted regarding the staining pattern of
Galectin-3 in thyroid neoplasms. The results
showed high frequency of staining in papillary
thyroid carcinomas only and no significant
staining in the other type of carcinomas.
Moreover, it also showed positive results in
follicular adenomas which made them conclude
that galectin-3 is not a sensitive marker if used
alone [8] Our study also shows the same results.
The latest meta-analysis indicated that galectin3 may be a potentially useful immuno-marker to
distinguish between patients with papillary
thyroid carcinoma (PTC) and patients without
116
Farwa et al.; JAMMR, 33(19): 111-119, 2021; Article no.JAMMR.73568
PTC. In addition, PTC patients with positive
expression of galectin-3 were prone to lymph
node metastasis [17]. Our study also gives us
the result that although galectin-3 is sensitive for
detecting papillary thyroid carcinomas but it is
not much sensitive in detecting other carcinomas
from benign lesions (adenomas) as shown in
Figs 4,5.
Another previous study also support that the use
of galectin-3, HBME-1, and cytokeratin-19 may
provide significant contributions in the differential
diagnosis of malignant thyroid tumors, although
focal galectin-3, HBME-1, and cytokeratin-19
expression may be encountered in benign
lesions. It has also concluded that cytokeratin-19
alone and its combinations with other markers
were more sensitive in accurate diagnosis of
papillary carcinoma than the other combinations.
Also these Immunohistochemical markers alone
cannot be used to differentiate between benign
and malignant lesions [18].
Another important point which was noted in this
study was that the carcinomas showing positive
galectin-3 gave mostly focal positivity rather than
the diffuse strong positivity in comparison to the
results of the study done by Manivannan et al
[18]. That study, which was done in 2012,
demonstrated that galectin-3 staining pattern is
significant in differentiating benign from
malignant follicular neoplasms as well as
follicular variant of papillary thyroid carcinoma.
Diffuse positivity for galectin-3 was associated
with malignant thyroid follicular neoplasms while
focal weak positivity favours adenomas. On the
other hand, previous study have demonstrated
that there was no marked difference in the
staining intensity for intra cytoplasmatic or
intranuclear expression of galectin-3 in benign
and malignant thyroid neoplasms [19].
The increased expression levels of galectin-3 on
Thin-Prep fine needle aspiration cytology were
associated with hypertrophy and cellular
hyperproliferation, pathophysiological situations
that are common to adenomas and thyroid
carcinomas [20-21]. A previous study compared
glypican-3 (a member of the glypican family of
heparan-sulfate proteoglycans bound to the
plasma membrane) with galectin-3 and
demonstrated that galectin-3 was more sensitive
in diagnosing thyroid carcinoma; however, it was
less specific in discriminating follicular-patterned
neoplasm [22]. Besides tissue expression, the
preoperative serum galectin-3 level had
diagnostic value, as it was significantly higher in
the cancer patients than in the control subjects
[23]. Our study doesn’t cover this aspect of
Galectin-3 role so further studies with larger
case numbers can be done to confirm it.
Galectin-3 is also used in combination with other
biomarkers for a differential diagnosis of thyroid
lesions. The most commonly combined
biomarkers are Hector Battifora mesothelial
epitope-1 (HBME-1) and cytokeratin-19 [24-27].
However galectin-3 may not be used as single
discriminators
between
follicular
thyroid
adenoma and carcinoma [24-27]. Some studies
show that galectin-3 and HBME-1 have an
excellent sensitivity and specificity for malignant
thyroid lesions (100 and 89.1%, respectively)
[26]. Despite core needle biopsies leading to the
diagnosis of the majority of thyroid nodules, the
accuracy is increased by also observing the
galectin-3, cytokeratin-19 and HBME-1 panels,
indicating their additional diagnostic value when
combined with routine histology and not when
used alone [24-27]. It was also reported that
galectin 3, cluster of differentiation (CD) and, to
an
extent,
HBME-1,
are
useful
immunocytochemical parameters with the
potential to support the fine needle aspiration
cytology diagnosis of PTC, particularly in
situations where the differential diagnoses is
complicated [28].
Studies have noted variable Galectin-3
expression in poorly differentiated thyroid
cancers also [29]. However, in majority of cases
(75% to 100% of reported cases) of anaplastic
thyroid carcinoma, Galectin-3 positivity was
identified suggesting that differentiated thyroid
carcinoma can progress or undergo anaplastic
transformation [26,29]. In the present study and
study by Herrmann et al., small number of cases
of MTC and poorly differentiated carcinoma are
reported with inconsistent Galectin-3 expression,
making diagnostic application of Galectin-3 in
these rare histological subgroups unlikely [30].
Zhu et al. studied CK-19, RET, Galectin-3 and
HBME-1 expression in papillary thyroid
carcinoma and found that expression in papillary
thyroid carcinoma was higher than that in benign
disease cases, but they concluded that, these
were not specific markers for papillary thyroid
carcinoma [31].
5. CONCLUSION
This
study
concluded
that
Galectin-3
immunohistochemical expression is seen among
both malignant and benign thyroid neoplasms
117
Farwa et al.; JAMMR, 33(19): 111-119, 2021; Article no.JAMMR.73568
although more in malignant ones. So, it cannot
be used alone for the routine diagnosis of
malignant thyroid lesions as it shows less
sensitivity and specificity .It also has expressed
limited role in differentiating between the benign
and the malignant thyroid neoplasms.
5.
DISCLAIMER
Authors have declared that no competing
interests exist. The products used for this
research are commonly and predominantly use
products in our area of research and country.
There is absolutely no conflict of interest
between the authors and producers of the
products because we do not intend to use these
products as an avenue for any litigation but for
the advancement of knowledge. Also, the
research was not funded by the producing
company rather it was funded by personal efforts
of the authors.
6.
7.
ETHICAL APPROVAL
8.
As per international standard or university
standard written ethical approval has been
collected and preserved by the authors.
9.
CONSENT
As per international standard or university
standard, patients’ written consent has been
collected and preserved by the authors.
10.
11.
COMPETING INTERESTS
Authors have
interests exist.
declared
that
no competing
REFERENCES
1.
2.
3.
4.
Braverman LE, Cooper D. Werner &
Ingbar's The Thyroid: A Fundamental and
th
Clinical Text. 10
ed. Philadelphia:
Lippincott Williams & Wilkins. 2012;10.
Sumana
BS,
ShaShidhar
S,
Shivarudrappa
AS.
Galectin-3
Immunohistochemical
Expression
in
Thyroid Neoplasms: Journal of Clinical
and Diagnostic Research. 2015;9:EC07.
Pellegriti G, Frasca F, Regalbuto C,
Squatrito S, Vigneri R. Worldwide
Increasing Incidence of Thyroid Cancer:
Update on Epidemiology and Risk Factors.
Journal of Cancer Epidemiology; 2013.
Dwivedi SS, Khandeparkar SG, Joshi AR,
Kulkarni MM, Bhayekar P, Jadhav A, et al.
12.
13.
14.
15.
118
Study of Immunohistochemical Markers
(CK-19,
CD-56,
Ki-67,
p53)
in
Differentiating Benign and Malignant
Solitary Thyroid Nodules with Special
Reference
to
Papillary
Thyroid
Carcinomas. Journal of Clinical and
Diagnostic Research. 2016;10:EC14-9.
Asif F, Ahmad MR, Majid A. Risk Factors
for Thyroid Cancer in Females Using a
Logit Model in Lahore, Pakistan. Asian
Pacific Journal of Cancer Prevention.
2015;16:6243-7.
Fortuna-Costa A, Gomes AM, Kozlowski
EO, Stelling MP, Pavão MS. Extracellular
Galectin-3 in Tumor Progression and
Metastasis. FrontOncol. 2014;4:138.
Trimboli P, Guidobaldi L, Amendola S,
Nasrollah N, Romanelli F, Attanasio D, et
al. Galectin-3 and HBME-1 Improve the
Accuracy of Core Biopsy in Indeterminate
Thyroid Nodules. Endocrine. 2016;52:3945.
Fukumori T, Kanayama H, Raz A. The
Role of Galectin-3 in Cancer Drug
Resistance. Drug Resistance Updates.
2007;10:101-8.
Hirabayashi J, Kasai K. The Family of
Metazoan
Metal-Independent
BetaGalactoside-Binding Lectins: Structure,
Function
and
Molecular
Evolution.
Glycobiology. 1993;3:297-304.
Dumic J, Dabelic S, Flogel M. Galectin-3:
An Open-Ended Story. Biochimica et
Biophysica Acta. 2006;1760:616-35.
Paron I, Scaloni A, Pines A, Bachi A, Liu
FT, Puppin C, Pandolfi M, Ledda L, Di
Loreto C, Damante G et al. Nuclear
Localization of Galectin-3 in Transformed
Thyroid Cells: A Role in Transcriptional
Regulation. Biochemical and Biophysical
Research Communications. 2003;302:
545-53.
Danguy A, Camby I, Kiss R. Galectins and
Cancer. Biochimica et Biophysica Acta.
2002;1572:285-93.
Van den Brule F, Califice S, Castronovo V.
Expression of Galectins in Cancer: A
Critical Review. Glycoconjugate Journal.
2004;19:537-42.
Johnson KD, Glinskii OV, Mossine VV,
Turk JR, Mawhinney TP, Anthony DC, et
al. Galectin-3 As a Potential Therapeutic
Target in Tumors Arising from Malignant
Endothelia. Neoplasia. 2007;9:662- 70.
Sawangareetrakul P, Srisomsap C,
Chokchaichamnankit D, Svasti J. Galectin3 Expression in Human Papillary Thyroid
Farwa et al.; JAMMR, 33(19): 111-119, 2021; Article no.JAMMR.73568
24. Paunovic I, Isic T, Havelka M, Tatic S,
Carcinoma.
Cancer
Genomics
&
Cvejic
D,
Savin
S.
Combined
Proteomics. 2008;5:117- 22.
Immunohistochemistry
for
Thyroid
16. Nangia-Makker P, Nakahara S, Hogan V,
Peroxidase, Galectin-3, CK19 and HBMERaz A. Galectin-3 in Apoptosis, a Novel
1 in Differential Diagnosis of Thyroid
Therapeutic
Target.
Journal
of
Tumors. APMIS. 2012;120:368–79.
Bioenergetics and Biomembranes. 2007;1:
25. Abd-El
Raouf
SM,
Ibrahim
TR.
79- 84.
Immunohistochemical
Expression
of
17. Tang W, Huang C, Tang C, Xu J, Wang H.
HBME-1 and Galectin-3 in the Differential
Galectin-3 may serve as a Potential
Diagnosis of Follicular-Derived Thyroid
Marker for Diagnosis and Prognosis in
Nodules. Pathology, Research and
Papillary Thyroid Carcinoma: A MetaPractice. 2014;210:971–8.
Analysis. Onco Targets and Therapy.
26. Trimboli P, Guidobaldi L, Amendola S,
2016;9:455–60.
Nasrollah N, Romanelli F, Attanasio D, et
18. Manivannan P, Siddaraju N, Jatiya L,
al. Galectin-3 and HBME-1 Improve the
Verma SK. Role of Pro-Angiogenic Marker
Accuracy of Core Biopsy in Indeterminate
Galectin-3 in Follicular Neoplasms of
Thyroid Nodules. Endocrine. 2016;52:39–
Thyroid. Indian Journal of Biochemistry
45.
and Biophysics. 2012;49:392–4.
27. Durry MF, Miskad UA, Leiwakabessy WN,
19. Sumana BS, Shashidhar S, Shivarudrappa
Cangara MH. Diagnostic Value of
AS.
Galectin-3
Immunohistochemical
Galectin-3
and
Hector
Battifora
Expression in Thyroid Neoplasms. Journal
Mesothelial Epitope (HBME)-1 as a
of Clinical and Diagnostic Research..
Marker for Malignancy in the Diagnosis of
2015;9:EC07–11.
Thyroid Lesions. Pathology International.
20. Papale F, Cafiero G, Grimaldi A, Marino
2016;48:S122–3.
G, Rosso F, Mian C, Barollo S, Pennelli G,
28. Das DK, Al-Waheeb SK, George SS, Haji
Sorrenti S, De Antoni E, Barbarisi A.
BI,
Mallik
MK.
Contribution
of
Galectin-3 Expression in Thyroid Fine
Immunocytochemical
Stainings
for
Needle Cytology (t-FNAC) Uncertain
galectin-3, CD44, and HBME1 to FineCases: Validation of Molecular Markers
Needle Aspiration Cytology Diagnosis of
and Technology Innovation. Journal of
Papillary Thyroid Carcinoma. Diagn
Cellular Physiology. 2013;228:968–74.
Cytopathol. 2014;42:498–505.
21. Salajegheh A, Dolan-Evans E, Sullivan E,
29. Bartolazzi A, Gasbarri A, Papotti M,
Irani S, Rahman MA, Vosgha H, Gopalan
Bussolati G, Lucante T, Khan A, et al.
V, Smith RA, Lam AK. The Expression
Application of an Immunodiagnostic
Profiles of the Galectin Gene Family in
Method for Improving Preoperative
Primary and Metastatic Papillary Thyroid
Diagnosis of Nodular Thyroid Lesions.
Carcinoma with Particular Emphasis on
Lancet. 2001;357:1644–50.
Galectin-1 and Galectin-3 Expression.
30. Herrmann ME, LiVolsi VA, Pasha TL,
Experimental and Molecular Pathology.
Roberts SA, Wojcik EM, Baloch ZW.
2014;96:212–8.
Immunohistochemical
Expression
of
22. Al-Sharaky DR, Younes SF. Sensitivity
Galectin-3 in Benign and Malignant
and Specificity of Galectin-3 and GlypicanThyroid Lesions. Archives of Pathology &
3 in Follicular-Patterned and other Thyroid
Laboratory Medicine. 2002;126:710–13.
Neoplasms. Journal of Clinical and
31. Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X,
Diagnostic Research. 2016;10:EC06–10.
Zhu X. Diagnostic Significance of CK19,
23. Yilmaz E, Karsidag T, Tatar C, Tüzün S.
RET, galectin-3 and HBME-1 Expression
Serum Galectin-3: Diagnostic Value for
for Papillary Thyroid Carcinoma. Journal of
Papillary Thyroid Carcinoma. Ulus Cerrahi
Clinical Pathology. 2010;63:786-9.
Derg. 2015;31:192–6.
_________________________________________________________________________________
© 2021 Farwa et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle4.com/review-history/73568
119